Mentholatum Aims To Ice FDA Warning Letter Concerns
This article was originally published in The Tan Sheet
Executive Summary
The Mentholatum Co. is continuing to sell its Migraine Ice cooling headache pads during ongoing negotiations with FDA regarding the labeling claims for the OTC device. FDA cited unapproved headache and migraine relief claims in an April 18 warning letter to the firm.
You may also be interested in...
Excedrin Tension Headache Cooling Pads Five-Month TV Campaign Underway
Bristol Myers-Squibb's Excedrin Tension Headache Cooling Pads provide "Quick Cool Comfort," claims a new national TV spot running through August.
Excedrin Tension Headache Cooling Pads Five-Month TV Campaign Underway
Bristol Myers-Squibb's Excedrin Tension Headache Cooling Pads provide "Quick Cool Comfort," claims a new national TV spot running through August.
Excedrin Tension Headache Cooling Pads Five-Month TV Campaign Underway
Bristol Myers-Squibb's Excedrin Tension Headache Cooling Pads provide "Quick Cool Comfort," claims a new national TV spot running through August.